Cargando…

Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis

The purpose of this study is to investigate the effect of hormone therapy (HT) on the oncological outcomes of endometrial cancer (EC) survivors. A systematic literature review was conducted in July 2021 to identify studies detailing the effect size for the relationship between HT use in EC and oncol...

Descripción completa

Detalles Bibliográficos
Autores principales: Londero, Ambrogio P., Parisi, Nadia, Tassi, Alice, Bertozzi, Serena, Cagnacci, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303659/
https://www.ncbi.nlm.nih.gov/pubmed/34300331
http://dx.doi.org/10.3390/jcm10143165
_version_ 1783727141285789696
author Londero, Ambrogio P.
Parisi, Nadia
Tassi, Alice
Bertozzi, Serena
Cagnacci, Angelo
author_facet Londero, Ambrogio P.
Parisi, Nadia
Tassi, Alice
Bertozzi, Serena
Cagnacci, Angelo
author_sort Londero, Ambrogio P.
collection PubMed
description The purpose of this study is to investigate the effect of hormone therapy (HT) on the oncological outcomes of endometrial cancer (EC) survivors. A systematic literature review was conducted in July 2021 to identify studies detailing the effect size for the relationship between HT use in EC and oncological outcomes (survival and disease recurrence). This included studies that evaluated the different recurrence rates among women treated for EC who subsequently underwent HT and those who did not. The collected studies were evaluated for quality, heterogeneity, and publication bias, and a pooled odds ratio (OR) or hazard ratio (HR) was calculated with a confidence interval of 95% (95% CI). In total, 5291 studies were collated, and after the review process, one randomized trial and seven observational studies were included, comprising 1801 EC survivors treated with HT and 6015 controls. The time-dependent analysis could be conducted for four studies, and considering the disease-free survival, the pooled HR of 0.90 (95% CI 0.28 to 2.87) showed no significant differences. However, among Black American women treated with continuous estrogen HT, the HR was 7.58 (95% CI 1.96 to 29.31), showing a significantly increased risk of recurrence for women in this ethnic group. Considering the pooled OR of all included studies 0.63 (95% CI 0.48 to 0.83), a significantly reduced risk of recurrence was found among EC survivors treated with HT. Considering the type of HT, the most risk-reducing was combined estrogen and progestin therapy and the cyclic regimen. Although supporting evidence is based mainly upon observational studies, evidence of no increased risk or even decreased risk was generally found, apart from in Black American women where a significantly increased recurrence risk was evident. The data are rather reassuring for the short-term administration of HT to symptomatic EC survivors. Future studies with a longer follow-up are necessary to better clarify the long-term effects of HT.
format Online
Article
Text
id pubmed-8303659
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83036592021-07-25 Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis Londero, Ambrogio P. Parisi, Nadia Tassi, Alice Bertozzi, Serena Cagnacci, Angelo J Clin Med Review The purpose of this study is to investigate the effect of hormone therapy (HT) on the oncological outcomes of endometrial cancer (EC) survivors. A systematic literature review was conducted in July 2021 to identify studies detailing the effect size for the relationship between HT use in EC and oncological outcomes (survival and disease recurrence). This included studies that evaluated the different recurrence rates among women treated for EC who subsequently underwent HT and those who did not. The collected studies were evaluated for quality, heterogeneity, and publication bias, and a pooled odds ratio (OR) or hazard ratio (HR) was calculated with a confidence interval of 95% (95% CI). In total, 5291 studies were collated, and after the review process, one randomized trial and seven observational studies were included, comprising 1801 EC survivors treated with HT and 6015 controls. The time-dependent analysis could be conducted for four studies, and considering the disease-free survival, the pooled HR of 0.90 (95% CI 0.28 to 2.87) showed no significant differences. However, among Black American women treated with continuous estrogen HT, the HR was 7.58 (95% CI 1.96 to 29.31), showing a significantly increased risk of recurrence for women in this ethnic group. Considering the pooled OR of all included studies 0.63 (95% CI 0.48 to 0.83), a significantly reduced risk of recurrence was found among EC survivors treated with HT. Considering the type of HT, the most risk-reducing was combined estrogen and progestin therapy and the cyclic regimen. Although supporting evidence is based mainly upon observational studies, evidence of no increased risk or even decreased risk was generally found, apart from in Black American women where a significantly increased recurrence risk was evident. The data are rather reassuring for the short-term administration of HT to symptomatic EC survivors. Future studies with a longer follow-up are necessary to better clarify the long-term effects of HT. MDPI 2021-07-18 /pmc/articles/PMC8303659/ /pubmed/34300331 http://dx.doi.org/10.3390/jcm10143165 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Londero, Ambrogio P.
Parisi, Nadia
Tassi, Alice
Bertozzi, Serena
Cagnacci, Angelo
Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis
title Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis
title_full Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis
title_fullStr Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis
title_full_unstemmed Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis
title_short Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis
title_sort hormone replacement therapy in endometrial cancer survivors: a meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303659/
https://www.ncbi.nlm.nih.gov/pubmed/34300331
http://dx.doi.org/10.3390/jcm10143165
work_keys_str_mv AT londeroambrogiop hormonereplacementtherapyinendometrialcancersurvivorsametaanalysis
AT parisinadia hormonereplacementtherapyinendometrialcancersurvivorsametaanalysis
AT tassialice hormonereplacementtherapyinendometrialcancersurvivorsametaanalysis
AT bertozziserena hormonereplacementtherapyinendometrialcancersurvivorsametaanalysis
AT cagnacciangelo hormonereplacementtherapyinendometrialcancersurvivorsametaanalysis